|Articles|October 12, 2021
Daily OTC Pearl: Vitamin B7 (Biotin)
Author(s)Saro Arakelians, PharmD
Biotin deficiency can cause thinning of the hair and a rash on the face.
Advertisement
OTC/Lifestyle Pearl of the Day: Vitamin B7 (Biotin)
Indication: Biotin (vitamin B7) is involved in a wide range of metabolic processes, both in humans and in other organisms, primarily related to the use of fats, carbohydrates, and amino acids.
Insight:
Biotin (vitamin B7) is a vitamin found in foods such as eggs, milk, and bananas. Biotin deficiency can cause thinning of thehair and arash on the face.- There isn't a good test for detecting low biotin levels, so it's usually identified by its symptoms, which include thinning
hair and a red, scaly rash around theeyes , nose, andmouth . - Biotin is used for biotin deficiency.
- It is also commonly used for
hair loss , brittle nails, and other conditions, but there is no good scientific evidence to support these uses. - Biotin
supplements may interfere with some lab tests. - There is no recommended daily allowance, but an adequate amount of biotin is thought to be 30 mcg a day. The
National Institutes of Health has not established how much is too much, but it doesn’t seem to be toxic even in oral doses as high as 200,000 mcg a day.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5